REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Moek KL, de Groot DJA, de Vries EGE, Fehrmann RSN. The antibody-drug conjugate target landscape across a broad range of tumour types. Ann Oncol 2017;28:3083-91.
3. Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 2017;16:315-37.
4. Lambert JM, Morris CQ. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther 2017;34:1015-35.
5. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
7. Lambert JM, Chari RV. Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014;57:6949-64.
8. Yamaguchi M, Hirose K, Hirai N. HER2 expression in gastrointestinal carcinoid tumors: high in intestinal but not in gastric tumors. Surg Today 2007;37:270-1.
9. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:63750.
10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
11. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704.
12. Beeram M, Krop IE, Burris HA, Girish SR, Yu W, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 2012;118:5733-40.
13. Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, et al. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res 2016;22:3755-63.
14. Kim SB, Wildiers H, Krop IE, Smitt M, Yu R, et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician’s choice in previously treated HER2-positive advanced breast cancer. Int J Cancer 2016;139:2336-42.
15. Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 2017;18:640-53.
16. Kulke MH, Muzikansky A, Clark J, Enzinger PC, Fidias P, et al. A phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest 2006;24:346-50.
17. Peng Z, Zou J, Zhang X, Yang Y, Gao J, et al. HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. Chin J Cancer Res 2015;27:163-71.
18. Janjigian YY, Riches JC, Ku GY, Imtiaz T, Capanu M, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab. J Clin Oncol 2015;33:63.
19. Ishimine Y, Goto A, Watanabe Y, Yajima H, Nakagaki S, et al. Loss of HER2 positivity after trastuzumab in HER2-positive gastric cancer: is change in HER2 status significantly frequent? Case Rep Gastrointest Med 2015;2015:132030.
20. Seo S, Ryu MH, Ahn JY, Park Y, Park SR, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of GASTric cancer HER2 reassessment study 3 (GASTHER3). J Clin Oncol 2017;35:27.
21. Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov 2018;8:49-58.
22. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
23. Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in pre-clinical models. Cancer Res 2016;76:2710-9.
24. Cortes J, Dieras V, Lorenzen S, Montemurro F, Riera-Knorrenschild J, et al. Abstract CT096: trastuzumab emtansine (T-DM1) + capecitabine in HER2-positive metastatic breast cancer (mBC) and HER2-positive locally advanced (LA)/metastatic gastric cancer (mGC): results from the phase I/randomized phase II TRAXHER2 study. Cancer Res 2018;78:CT096.
25. Gelmon KA, Vidal M, Sablin MP, Serpanchy R, Soberino J, et al. Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients with HER2-positive MBC: MO28230 TRAX-HER2 phase 1 results. J Clin Oncol 2014;32:606.
26. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 2016;22:5097-108.
27. Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer 2017;141:1682-9.
28. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 2016;107:1039-46.
29. Tamura K, Shitara K, Naito Y, Shimomura A, Fujiwara Y, et al. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: phase 1 dose escalation. Ann Oncol 2016;27:LBA17.
30. Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol 2017;18:1512-22.
31. Iwasa S, Shitara K, Takahashi S, Park H, Kadowaki S, et al. Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer. J Clin Oncol 2018;36:118.
32. Tsurutani J, Doi T, Iwata H, Takahashi S, Modi S, et al. 409PUpdated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies. Ann Oncol 2017;28:mdx367.042.
33. Bergstrom DA, Bodyak N, Park PU, Yurkovetskiy A, DeVit M, et al. Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer. Cancer Res 2016; doi: 10.1158/1538-7445.SABCS15-P4-14-28.
34. Bergstrom DA, Bodyak N, Yurkovetskiy A, Park PU, DeVit M, et al. Abstract LB-231: a novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors. Cancer Res 2015; doi: 10.1158/1538-7445.AM2015-LB-231.
35. Hamilton EP, Barve MA, Bardia A, Beeram M, Bendell JC, et al. Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors. J Clin Oncol 2018; doi: 10.1200/JCO.2018.36.15_suppl.2546.
36. Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, et al. A Biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 2016;29:117-29.
37. Pegram M, Hamilton E, Tan AR, Storniolo AM, Elgeioushi N, et al. 47O Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer. Ann Oncol 2018;29:iii7-9.
38. Verheijden G, Beusker P, Ubink R, van der Lee M, Groothuis P, et al. Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC). J Clin Oncol 2014;32:626.
39. van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther 2015;14:692-703.
40. Black JD, Lopez S, Cocco E, Bellone S, Bonazzoli E, et al. Abstract 2461: SYD985, a novel HER2-targeting antibody-drug conjugate, shows strong antitumor activity in primary USC cell lines with low (1+) and moderate (2+) HER2/Neu expression. Cancer Res 2015;75:2461.
41. Dokter WHA, van der Lee M, Groothuis P, van Achterberg T, Loosveld E, et al. Abstract 2652: In vitro and in vivo antitumor activity of SYD985, a novel HER2-targeting ADC: a comparison with T-DM1. Cancer Res 2014;74:2652.
42. Saura C, Thistlethwaite F, Banerji U, Lord S, Moreno V, et al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. J Clin Oncol 2018;36:1014.
43. Humphreys RC, Kirtely J, Hewit A, Biroc S, Knudsen N, et al. Abstract 639: site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers. Cancer Res 2015;75:639.
44. Zammarchi F, Reinert HW, Janghra N, Corbett S, Mellinas-Gomez M, et al. Abstract 52: mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors. Cancer Res 2017;77:52.
45. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
47. Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, et al. Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol 2016;34:4171-9.
48. NIH. An efficacy study of MORAb-009 in subjects with pancreatic cancer. Available from: https://ClinicalTrials.gov/show/NCT00570713. [Last accessed on 3 Dec 2018].
49. Terwisscha van Scheltinga AG, Ogasawara A, Pacheco G, Vanderbilt AN, Tinianow JN, et al. Preclinical efficacy of an antibody-drug conjugate targeting mesothelin correlates with quantitative 89 Zr-immunoPET. Mol Cancer Ther 2017;16:134-142.
50. Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, et al. Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther 2016;15:439-47.
51. Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 2014;13:1537-48.
52. Blumenschein GR, Hassan R, Moore KN, Santin A, Kindler HL, et al. Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). J Clin Oncol 2016;34:2509.
53. Adjei AA, Bekaii-Saab TS, Berlin J, Philip PA, Mercade TM, et al. Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies. J Clin Oncol 2018;36:TPS2607.
54. Chokshi S, Hochster HS. An open-label, phase II study of intravenous anetumab ravtansine, an anti-mesothelin antibody drug conjugate, in pretreated mesothelin-expressing advanced pancreatic cancer. J Clin Oncol 2018;36:TPS540.
55. Zhao XY, Subramanyam B, Sarapa N, Golfier S, Dinter H. Novel antibody therapeutics targeting mesothelin in solid tumors. Clin Cancer Drugs 2016;3:76-86.
56. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, et al. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol 2005;36:170-9.
57. Danaee H, Kalebic T, Wyant T, Fassan M, Mescoli C, et al. Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers. PLoS One 2017;12:e0189953.
58. Schreiber AR, Nguyen A, Bagby SM, Yacob B, Quackenbush K, et al. Abstract B050: evaluation of TAK-264, a novel antibody-drug conjugate in pancreatic cancer cell lines and patient-derived xenograft models. Mol Cancer Ther 2018;17:B050.
59. Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, et al. Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies. Clin Cancer Res 2016;22:5049-57.
60. Bang YJ, Takano T, Lin CC, Fasanmade A, Yang H, et al. TAK-264 (MLN0264) in previously treated asian patients with advanced gastrointestinal carcinoma expressing guanylyl cyclase C: results from an open-label, non-randomized phase 1 study. Cancer Res Treat 2018;50:398-404.
61. Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, et al. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs 2017;35:634-41.
62. Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, et al. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. Invest New Drugs 2017;35:235-41.
63. Abu-Yousif AO, Bannerman BM, Cvet D, Gallery M, Ganno ML, et al. Abstract B120: TAK-164, a GCC-targeted antibody-drug conjugate (ADC) for the treatment of colorectal cancers and other GI malignancies. Mol Cancer Ther 2018;17:B120.
64. Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev 2013;32:643-71.
65. Decary S, Berne PF, Nicolazzi C, Lefebvre AM, Dabdoubi T, et al. Abstract 1688: a novel anti-CEACAM5 maytansinoid-antibody-drug conjugate for the treatment of colorectal, lung and gastric tumors. Cancer Res 2015;75:1688.
66. Gazzah A, Stjepanovic N, Ryu MH, Tabernero J, Soria JC, et al. First-in-human phase I trial of the anti-CEACAM5 antibody-drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848). Eur J Cancer 2016;69:S14-5.
67. Govindan SV, Cardillo TM, Rossi EA, McBride WJ, Sharkey RM, et al. IMMU-130, a unique antibody-drug conjugate (ADC) of SN-38 targeting CEACAM5 antigen: pre-clinical basis for clinical activity in metastatic colorectal cancer (mCRC). J Clin Oncol 2015;33:625.
68. Cardillo TM, Sharkey RM, Govindan SV, Donnel J, Zalath M, et al. Abstract 4081: superior SN-38 pharmacodynamic and tumor-accretion profiles of labetuzumab govitecan (IMMU-130) versus irinotecan in experimental human colonic cancer models. Cancer Res 2017;77:4081.
69. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009;15:6052-61.
70. Segal NH, Dotan E, Berlin JD, Starodub AN, Guarino MJ, et al. Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): initial clinical results of two phase I studies. Cancer Res 2014;74:CT211.
71. Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, et al. Phase I/II trial of labetuzumab govitecan (anti-CEACAM5/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol 2017;35:3338-46.
72. Govindan SV, Cardillo TM, Rossi EA, Trisal P, McBride WJ, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm 2015;12:1836-47.
73. Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 2004;10:4363-8.
74. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
75. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21:211-22.
76. Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, et al. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol 2008;62:911-9.
77. Shapiro GI, Vaishampayan UN, LoRusso P, Barton J, Hua S, et al. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs 2017;35:315-23.
78. Naganuma H, Kono K, Mori Y, Takayoshi S, Stern PL, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res 2002;22:1033-8.
79. Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 1995;5:269-74.
80. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, et al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 1994;69:899-902.
81. Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, et al. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res 2011;71:4236-46.
82. Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther 2013;12:38-47.
83. Mao S, Garcia A, Chen T, Chaerkady R, Marreno A, et al. Abstract 2064: tumor cells treated with a PBD-based antibody-drug conjugate targeting 5T4 develop acquired resistance due to 5T4 down-regulation and response to alternate therapeutics. Cancer Res 2017; doi: 10.1158/1538-7445.AM2017-2064.
84. Stern PL, Harrop R. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. Cancer Immunol Immunother 2017;66:415-26.
85. Del Campo JM, Birrer M, Davis C, Fujiwara K, Gollerkeri A, et al. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol 2016;142:62-9.
86. Shor B, Kahler J, Dougher M, Xu J, Mack M, et al. Enhanced antitumor activity of an anti-5T4 antibody-drug conjugate in combination with PI3K/mTOR inhibitors or taxanes. Clin Cancer Res 2016;22:383-94.
87. Brown JS, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer 2018;118:312-24.
88. Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med 2015;7:315ra188.
89. Mignot F, Ajgal Z, Xu H, Geraud A, Chen JY, et al. Concurrent administration of anti-HER2 therapy and radiotherapy: systematic review. Radiother Oncol 2017;124:190-9.